AbbVie (ABBV) Issues Encouraging Update on SURVEYOR-I and SURVEYOR-II Studies in HCV
Tweet Send to a Friend
AbbVie (NYSE: ABBV) announced data from the SURVEYOR studies of its investigational HCV regimen, ABT-493, an NS3/4A protease inhibitor, and ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
